Related Experiment Video
Updated: Jul 13, 2026
PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
Published on: December 28, 2017
Novalis radiosurgery of optic gliomas in children: preliminary report
Seong Rok Han1, Sang Won Yoon, Gi Taek Yee
1Department of Neurosurgery, Ilsan Paik Hospital, College of Medicine, Inje University, Goyang, Korea. hsrkmj@ilsanpaik.ac.kr
Insights
Novalis radiosurgery (RS) effectively treated pediatric optic gliomas, achieving complete tumor control without significant side effects. Further long-term studies are needed to confirm these promising results for children.
Area of Science:
- Pediatric Oncology
- Neurosurgery
- Radiation Oncology
Background:
- Optic gliomas are tumors affecting the optic nerve or brain.
- Effective treatment is crucial for preserving vision and neurological function in children.
Purpose of the Study:
- To evaluate the effectiveness and safety of Novalis radiosurgery (RS) for treating pediatric optic gliomas.
Main Methods:
- Retrospective analysis of four pediatric patients treated with Novalis RS.
- Mean target dose of 44 Gy and fractionation dose of 1.58 Gy.
- Follow-up included MRI, ophthalmologic, and endocrine examinations.
Main Results:
- All patients survived with a mean follow-up of 54 months.
- Complete local tumor control was achieved in all cases.
- No clinically significant morbidity, including endocrine dysfunction, was observed.
Conclusions:
- Novalis radiosurgery shows potential as an effective treatment for pediatric optic gliomas.
- Long-term follow-up is necessary to fully assess efficacy and potential late side effects.
Aim:
To evaluate the effectiveness of Novalis radiosurgery (RS) in children with optic gliomas.
Methods:
Four pediatric patients (1 male and 3 female) were treated for optic gliomas with Novalis RS in our institution between February 2002 and July 2002. Their mean age was 12 (range 5-16) years at presentation for Novalis RS. The mean target dose was 44 (range 41-45) Gy, with a mean fractionation dose of 1.58 (range 1.5-1.65) Gy. Follow-up included magnetic resonance imaging and ophthalmologic and endocrine examinations.
Results:
The mean follow-up period was 54 (range 50-58) months. During the follow-up period, all patients were alive. Local control of the tumor was obtained in all patients. None of the patients showed clinically relevant morbidity, especially endocrine dysfunction.
Conclusions:
Novalis RS may be an excellent treatment method for optic gliomas in children. However, long-term follow-up is required for further evaluation of efficacy and potential side effects.
